Respiratory System Drugs Practice Questions

Q: Which of the following drugs is contraindicated in patients with asthma due to its potential to cause bronchoconstriction?

Propranolol (non-selective beta-blocker). ***Propranolol (non-selective beta-blocker)*** - **Non-selective beta-blockers** block both **beta-1 and beta-2 receptors** - Blockade of **beta-2 receptors** in bronchial smooth muscle leads to **bronchoconstriction** in susceptible individuals like asthmatics - This effect can trigger or worsen asthma symptoms, making it an **absolute contraindication** in patients with asthma - Cardioselective beta-blockers (like atenolol) are relatively safer but still used with caution *Lisinopril (ACE inhibitor)* - ACE inhibitors can cause a **dry cough** due to accumulation of bradykinin, not bronchoconstriction - The cough is due to bradykinin and substance P accumulation, not bronchospasm - Generally **safe in asthma** patients - Angioedema is a rare but serious side effect, unrelated to bronchial effects *Atorvastatin (statin)* - **Statins** (HMG-CoA reductase inhibitors) are used to lower cholesterol - No direct effects on **bronchial tone** or respiratory function - **Safe for use** in patients with asthma - No contraindications related to respiratory disease *Amlodipine (calcium channel blocker)* - **Dihydropyridine calcium channel blockers** cause vascular smooth muscle relaxation - Do **not cause bronchoconstriction** and are safe in asthma patients - May have mild **bronchodilatory effects** due to smooth muscle relaxation - No respiratory contraindications

Q: In the management of asthma, which drug class is the most effective for long-term control and prevention of symptoms?

Corticosteroids. **Corticosteroids** (Correct Answer) - **Inhaled corticosteroids** are the most effective anti-inflammatory medications for long-term control of persistent asthma, reducing airway hyperresponsiveness and preventing exacerbations. - They work by suppressing the inflammatory response in the airways, leading to decreased mucus production and swelling. - Inhaled corticosteroids are the **cornerstone of asthma management** as per GINA (Global Initiative for Asthma) guidelines. *Beta-agonists* (Incorrect) - **Short-acting beta-agonists (SABAs)** are primarily used as **rescue medications** for acute symptom relief, as they rapidly relax airway smooth muscle. - **Long-acting beta-agonists (LABAs)** are used for long-term control but generally in combination with inhaled corticosteroids, not as monotherapy, due to their limited anti-inflammatory action. - LABAs alone do not address the underlying inflammation in asthma. *Leukotriene modifiers* (Incorrect) - These drugs, such as montelukast, block the action of **leukotrienes**, which are inflammatory mediators. - While effective for some patients, they are generally **less potent than inhaled corticosteroids** for overall asthma control and are often used as **add-on therapy** or alternative for mild asthma. - They may be particularly useful in aspirin-sensitive asthma and exercise-induced bronchoconstriction. *Anticholinergics* (Incorrect) - **Short-acting anticholinergics** (e.g., ipratropium) are used as **bronchodilators** and can be helpful in acute asthma exacerbations or for patients who cannot tolerate beta-agonists. - **Long-acting anticholinergics** are primarily used in **COPD management** rather than as first-line asthma therapy. - Their role in asthma is limited compared to corticosteroids, which address the underlying inflammatory pathophysiology.

Q: Which of the following is a leukotriene receptor antagonist used in the management of asthma?

Montelukast. ***Correct Answer: Montelukast*** - **Montelukast** is a selective and orally active **leukotriene receptor antagonist** that specifically blocks the cysteinyl leukotriene 1 (CysLT1) receptor. - By blocking leukotrienes, it helps to **reduce inflammation**, bronchoconstriction, and mucus secretion, thus preventing asthma symptoms. - It is particularly useful for **exercise-induced asthma** and as an add-on therapy to inhaled corticosteroids. *Incorrect: Albuterol* - **Albuterol** is a **short-acting beta-2 adrenergic agonist (SABA)**, primarily used as a **rescue inhaler** for acute asthma symptoms. - It works by **relaxing the smooth muscles** in the airways, leading to bronchodilation, but does not target leukotrienes. *Incorrect: Fluticasone* - **Fluticasone** is an **inhaled corticosteroid (ICS)**, a cornerstone of long-term asthma control. - It reduces airway inflammation by **suppressing the immune response** at a cellular level, rather than blocking leukotriene receptors. *Incorrect: Salmeterol* - **Salmeterol** is a **long-acting beta-2 adrenergic agonist (LABA)**, used for long-term asthma control in combination with an inhaled corticosteroid. - It provides prolonged bronchodilation by **stimulating beta-2 receptors**, but does not act on leukotriene pathways.

Q: Which bronchodilator drug is considered the first-line therapy for acute asthma attacks due to its rapid onset of action?

Salbutamol. ***Salbutamol*** - **Salbutamol** is a **short-acting beta-2 agonist (SABA)**, which means it rapidly relaxes the smooth muscles of the airways [1], [4]. - Its **quick onset of action** (within minutes) makes it the preferred drug for immediate relief of **acute asthma symptoms** like shortness of breath and wheezing [1], [3]. *Salmeterol* - **Salmeterol** is a **long-acting beta-2 agonist (LABA)**, providing bronchodilation for up to 12 hours [5]. - It is used for **maintenance therapy** to prevent asthma attacks, not for acute relief, and should always be used in combination with an inhaled corticosteroid. *Ipratropium* - **Ipratropium** is a **short-acting anticholinergic** that blocks muscarinic receptors in the airways, leading to bronchodilation [2]. - While it can be used as an **adjunct to SABAs** in severe acute asthma, it has a slower onset of action and is not considered first-line monotherapy for acute attacks. *Tiotropium* - **Tiotropium** is a **long-acting anticholinergic** primarily used for the maintenance treatment of **COPD** and sometimes as an add-on therapy for severe asthma [5]. - Its **slow onset** and prolonged action make it unsuitable for the immediate relief of acute asthma symptoms.

Q: A 45-year-old man with chronic obstructive pulmonary disease (COPD) is experiencing worsening symptoms despite using short-acting bronchodilators. Which long-acting beta-agonist could be recommended for maintenance therapy?

Salmeterol. ***Salmeterol*** - Salmeterol is a **long-acting beta-agonist (LABA)**, indicated for maintenance therapy in COPD due to its prolonged bronchodilatory effect. - LABAs like salmeterol are crucial for **symptom control and reducing exacerbations** in patients with persistent COPD symptoms. *Albuterol* - Albuterol is a **short-acting beta-agonist (SABA)**, primarily used for **rescue relief** of acute bronchospasm, not for maintenance therapy. - Its effects last for only 4-6 hours, making it unsuitable for sustained symptom control in COPD. *Pirbuterol* - Pirbuterol is also a **short-acting beta-agonist (SABA)**, similar to albuterol, providing quick but temporary relief. - It is not recommended for daily, long-term maintenance treatment of COPD. *Orciprenaline* - Orciprenaline is an older, **short-acting beta-agonist** no longer commonly used due to a less favorable side effect profile and shorter duration of action. - It is not considered a modern first-line treatment for either acute relief or maintenance in COPD.

Q: In assessing treatment options for a patient with severe asthma, what would be the most immediate action to alleviate symptoms?

Short-acting beta-agonist inhaler use. ***Short-acting beta-agonist inhaler use*** - **Short-acting beta-agonists (SABAs)** provide rapid relief of acute asthma symptoms by **bronchodilation**, making them the most immediate and effective action for symptom alleviation [1]. - They work by relaxing the **smooth muscles of the airways**, opening them up and easing breathing during an asthma attack. *Long-term corticosteroid therapy* - **Long-term corticosteroid therapy** is a cornerstone of **asthma control and prevention of exacerbations**, but it does not provide immediate relief for acute symptoms [2]. - Its effects on reducing airway inflammation and hyper-responsiveness take days to weeks to become apparent. *Introduction of leukotriene modifiers* - **Leukotriene modifiers** help in long-term asthma control by blocking specific inflammatory pathways, but they do not offer immediate relief during acute exacerbations [1]. - Their primary role is to reduce inflammation and prevent symptoms over time, typically acting over several days to weeks. *Gradual increase in physical activity* - A **gradual increase in physical activity** can improve overall lung function and cardiovascular health in patients with stable asthma, but it is not an immediate treatment for symptom alleviation. - In fact, vigorous physical activity can sometimes trigger asthma symptoms if not properly managed or if the patient is not well-controlled.

Q: Which of the following is NOT an inhalational steroid?

Betamethasone. ***Betamethasone*** - **Betamethasone** is a potent **systemic corticosteroid** commonly used orally, parenterally, or topically for various inflammatory conditions. - It is **not formulated for inhalation** due to its systemic activity which would lead to significant side effects if administered via the respiratory tract. *Beclomethasone* - **Beclomethasone** is a well-known **inhaled corticosteroid (ICS)** used for maintenance therapy in asthma and COPD. - It works by reducing airway inflammation locally with minimal systemic absorption. *Budesonide* - **Budesonide** is another widely used **inhaled corticosteroid (ICS)**, effective in managing asthma and COPD. - It is also available in nebulized formulations for children and individuals unable to use metered-dose inhalers. *Fluticasone acetonide* - **Fluticasone acetonide** is a potent **inhaled corticosteroid (ICS)** frequently prescribed for long-term control of asthma and allergic rhinitis. - It has high topical anti-inflammatory activity and low systemic bioavailability, making it suitable for inhalation.

Q: In which condition is the use of PGF2α analogues contraindicated?

Bronchial asthma. ***Bronchial asthma*** - PGF2α analogues, particularly **carboprost**, are **uterotonics** that can cause **bronchoconstriction** and are thus contraindicated in patients with **bronchial asthma**. - This effect is due to the activation of prostanoid receptors in the airways, leading to the constriction of bronchial smooth muscle. *Postpartum hemorrhage* - **PGF2α analogues** like **carboprost** are frequently used to treat **postpartum hemorrhage** due to their potent uterotonic effects, which help to contract the uterus and stop bleeding. - This condition is an **indication**, not a contraindication, for PGF2α analogue use. *Glaucoma* - **Prostaglandin analogues** (e.g., latanoprost, travoprost), which are often PGF2α derivatives, are a **first-line treatment for glaucoma** as they effectively lower **intraocular pressure**. - Therefore, glaucoma is an **indication** for some PGF2α analogues, not a contraindication. *Priapism* - **PGF2α analogues** are generally **not directly implicated in the treatment or contraindication of priapism**, which is often managed with alpha-agonists, aspiration, or surgical shunts. - While prostaglandins (like PGE1) can induce erections, PGF2α analogues are not typically used in this context and do not pose a direct contraindication for priapism.

Q: Advantage of formoterol over salmeterol is?

It has got a faster onset of action. ***It has got a faster onset of action*** - **Formoterol** has a **faster onset of action** (within 1-3 minutes) compared to salmeterol, making it suitable for both maintenance and quick relief of bronchoconstriction. - This rapid onset allows it to act similarly to short-acting beta-agonists (SABAs) for symptom control, while also providing long-acting benefits. *Both can be used for prophylaxis in asthmatics* - While both **formoterol** and **salmeterol** are **long-acting beta-2 agonists (LABAs)** [1] and are used for prophylaxis (maintenance therapy) in asthma, this statement does not highlight an advantage of formoterol over salmeterol. - Their primary role is in preventing symptoms, not necessarily in acute relief due to this shared characteristic. *It is a long-acting beta 2 agonist* - Both **formoterol** and **salmeterol** are **long-acting beta-2 agonists** [1]. - This is a shared characteristic and not a unique advantage of formoterol over salmeterol. *It has minimal beta 1 agonistic action* - Both **formoterol** and **salmeterol** are *highly selective* for **beta-2 receptors** [1], meaning they both have minimal beta-1 agonistic action. - Therefore, this is not a distinguishing advantage of formoterol over salmeterol.

Q: What is the classification of Omalizumab?

Anti-IgE antibody. ***Anti-IgE antibody*** - **Omalizumab** is a **monoclonal antibody** specifically designed to bind to free **immunoglobulin E (IgE)** in the blood [1], [2]. - By binding IgE, it prevents IgE from attaching to its receptors on **mast cells** and **basophils**, thus inhibiting the release of inflammatory mediators involved in allergic reactions [3]. *Anti-IgM antibody* - **Anti-IgM antibodies** are not used as a therapeutic intervention for asthma or allergies as IgM is primarily involved in primary immune responses and forms a pentamer. - Therapeutic antibodies typically target specific molecules involved in disease pathology, and IgM is not a primary target for allergic conditions. *Anti-IgG antibody* - **Anti-IgG antibodies** are generally not used in the treatment of allergic conditions or asthma, as **IgG** is mainly involved in secondary immune responses and provides long-term immunity. - While IgG can be targeted in some autoimmune conditions, it is not the mechanism of action for omalizumab. *Anti-IgD antibody* - **Anti-IgD antibodies** have no known therapeutic application in allergic asthma or similar conditions. - **IgD** is found on the surface of B cells and plays a role in B cell activation, but it is not directly involved in the allergic cascade targeted by omalizumab.

Question 1

Which of the following drugs is contraindicated in patients with asthma due to its potential to cause bronchoconstriction?

Accepted Answer

Propranolol (non-selective beta-blocker)

Answer

Lisinopril (ACE inhibitor)

Answer

Atorvastatin (statin)

Answer

Amlodipine (calcium channel blocker)

Question 2

In the management of asthma, which drug class is the most effective for long-term control and prevention of symptoms?

Accepted Answer

Corticosteroids

Answer

Beta-agonists

Answer

Leukotriene modifiers

Answer

Anticholinergics

Question 3

Which of the following is a leukotriene receptor antagonist used in the management of asthma?

Accepted Answer

Montelukast

Answer

Albuterol

Answer

Fluticasone

Answer

Salmeterol

Question 4

Which bronchodilator drug is considered the first-line therapy for acute asthma attacks due to its rapid onset of action?

Accepted Answer

Salbutamol

Answer

Salmeterol

Answer

Ipratropium

Answer

Tiotropium

Question 5

A 45-year-old man with chronic obstructive pulmonary disease (COPD) is experiencing worsening symptoms despite using short-acting bronchodilators. Which long-acting beta-agonist could be recommended for maintenance therapy?

Accepted Answer

Salmeterol

Answer

Albuterol

Answer

Pirbuterol

Answer

Orciprenaline

Question 6

In assessing treatment options for a patient with severe asthma, what would be the most immediate action to alleviate symptoms?

Accepted Answer

Short-acting beta-agonist inhaler use

Answer

Long-term corticosteroid therapy

Answer

Introduction of leukotriene modifiers

Answer

Gradual increase in physical activity

Question 7

Which of the following is NOT an inhalational steroid?

Accepted Answer

Betamethasone

Answer

Beclomethasone

Answer

Budesonide

Answer

Fluticasone acetonide

Question 8

In which condition is the use of PGF2α analogues contraindicated?

Accepted Answer

Bronchial asthma

Answer

Glaucoma

Answer

Priapism

Answer

Post partum hemorrhage

Question 9

Advantage of formoterol over salmeterol is?

Accepted Answer

It has got a faster onset of action

Answer

Both can be used for prophylaxis in asthmatics

Answer

It is a long-acting beta 2 agonist

Answer

It has minimal beta 1 agonistic action

Question 10

What is the classification of Omalizumab?

Accepted Answer

Anti-IgE antibody

Answer

Anti-IgM antibody

Answer

Anti-IgG antibody

Answer

Anti-IgD antibody

Respiratory System Drugs — MCQs

Respiratory System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?